PP 1: Selective Src Family Tyrosine Kinase Inhibitor for Research

Executive Summary: PP 1 is a chemically defined small molecule inhibitor of Src family non-receptor tyrosine kinases, with nanomolar IC50 values for Lck and Fyn (product information). It is widely used to dissect signaling pathways in cancer and immune cell models, with selective suppression of Lyn activity and minimal off-target effect on Syk kinases. In vitro, PP 1 blocks RET oncogene-driven transformation with high specificity (Keller et al. 2023). In vivo studies demonstrate reduced protein tyrosine phosphorylation and T cell proliferation under PP 1 treatment. The compound is supplied by APExBIO as a high-purity, QC-verified reagent.

Biological Rationale

Src family kinases (SFKs) regulate critical cellular processes including proliferation, adhesion, migration, and survival. Dysregulation of SFKs is implicated in tumorigenesis, immune evasion, and therapy resistance. Targeting SFKs is therefore a strategy in both cancer biology and immunomodulation. Key kinases in this family—Lck, Fyn, and Lyn—mediate T cell receptor (TCR) signaling and drive oncogenic pathways such as those involving the RET proto-oncogene. Selective inhibition allows researchers to dissect these pathways with minimal confounding from off-target effects, supporting precision cancer therapy development and immune signaling studies (reference study).

Mechanism of Action of PP 1 (Src family tyrosine kinase inhibitor)

PP 1 (1-tert-butyl-3-(4-methylphenyl)pyrazolo[3,4-d]pyrimidin-4-amine, MW 281.36, C16H19N5) is a small molecule that competitively inhibits the ATP-binding site of Src family kinases. It exhibits potent inhibition of Lck (IC50 = 5 nM) and Fyn (IC50 = 6 nM) (APExBIO). PP 1 demonstrates high selectivity by sparing unrelated kinases such as Syk, as shown in RBL-2H3 cell models. The compound’s action leads to suppression of downstream phosphorylation events, attenuating key signaling nodes involved in cell proliferation and immune activation.

Evidence & Benchmarks

• PP 1 inhibits Lck and Fyn kinase activity with IC50 values of 5 nM and 6 nM, respectively (APExBIO).
• Selective inhibition of Lyn kinase in RBL-2H3 cells observed, with no measurable impact on Syk kinase at equivalent concentrations (APExBIO).
• RET oncogene-driven transformation is suppressed by PP 1 at nanomolar concentrations in vitro (Keller et al. 2023).
• In vivo, PP 1 reduces protein tyrosine phosphorylation and inhibits T cell proliferation (APExBIO).
• PP 1 is insoluble in water but dissolves in DMSO (≥7.03 mg/mL) and ethanol (≥20.6 mg/mL with ultrasonic assistance) (APExBIO).

For a detailed comparison of PP 1 with other Src inhibitors and troubleshooting guidance, see this resource, which this article extends by providing updated molecular benchmarks and protocol integration strategies.

Applications, Limits & Misconceptions

PP 1 is primarily used in cancer research and immune signaling studies to probe the role of specific Src kinases in cell models. It enables selective dissection of Lck and Fyn-driven pathways, including T cell activation modulation and RET-driven oncogenesis. However, its use is limited to research applications and is not approved for clinical therapy. The compound’s selectivity profile should be verified in each experimental context due to potential cell-type or species-specific differences in kinase expression.

Common Pitfalls or Misconceptions

• PP 1 is not a pan-kinase inhibitor; it does not inhibit Syk or most non-Src kinases at standard working concentrations.
• Long-term storage of PP 1 solutions is not recommended due to potential compound degradation (APExBIO).
• PP 1 is not clinically approved; its use is restricted to laboratory research settings.
• Water insolubility requires careful solvent selection to avoid precipitation or loss of potency.
• Cellular context may affect observed selectivity—validate kinase inhibition in each system.

For further discussion on troubleshooting and assay design, see this guide, which this article updates with new benchmarks and storage recommendations.

Workflow Integration & Parameters

Protocol Parameters

• Solvent preparation: Dissolve PP 1 in DMSO to a final concentration ≥7.03 mg/mL; ethanol can be used (≥20.6 mg/mL) with ultrasonic assistance.
• Storage: Store solid PP 1 desiccated at 4°C; avoid long-term storage of solutions.
• Working concentration: Typical in vitro assays use 10–100 nM for Src inhibition; titrate as needed for cell type and endpoint.
• Shipping conditions: Ship with blue ice for small molecule stability.
• Quality control: Use only lots with validated HPLC, MS, and NMR documentation (supplied by APExBIO).

For advanced integration in Src signaling or RET oncogene models, see this analysis, which this dossier clarifies by specifying validated working concentrations and solubility data.

Conclusion & Outlook

PP 1 remains a gold-standard selective Src family tyrosine kinase inhibitor, enabling precise mechanistic studies in cancer and immunology research. Its validated specificity, robust quality control, and ease of integration make it an essential tool for dissecting kinase-driven pathways and evaluating resistance mechanisms. As recent work highlights the interplay of kinase signaling and metabolic adaptation in therapy-resistant cancer, the use of selective inhibitors like PP 1 is crucial for advancing targeted research (Keller et al. 2023). Future innovation will depend on such rigorously benchmarked reagents and transparent reporting of protocol parameters.